Please assess the completion status of the following clinical trial:

Trial Title: Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current or ex-smoker with at least a 10-year pack history~* COPD, defined as forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) \< 70% and FEV1% predicted \< 80%~* 25-hydroxy vitamin D3 (25\[OH\]D3) level less than 20 ng/mL prior to study initiation~* Willingness to comply with study guidelines~* Willingness to avoid alternative/additional vitamin D3 supplementation for the duration of the trial~* Subject must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~Exclusion Criteria:~* Personal history of lung cancer or head and neck cancer~* History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue)~* History of known thyroid disease~* History of known sarcoid disease~* History of known abnormalities in calcium metabolism~* Hypercalcemia (serum calcium in excess of laboratory upper limit normal \[ULN\])~* Self-reported consumption of more than 4 alcoholic drinks per day~* Use of anti-seizure medications phenobarbital or phenytoin, which can disrupt vitamin D metabolism~* History of known renal dysfunction~* History of known nephrolithiasis (kidney stones)~* Current use of supplemental oxygen~* Inability to exercise due to musculoskeletal issue, osteoarthritis or underlying cardiac disease~* Current participation in a cancer intervention prevention study, except for smoking cessation~* Any condition which in the Investigator's opinion deems the subject an unsuitable candidate to receive study drug~* Inability to swallow pills~* Vitamin D supplementation \> 2,000 IU/day of vitamin D within 30 days prior to enrollment~* Positive Pregnancy Test

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control arm (multivitamin, placebo) (Type: ACTIVE_COMPARATOR): Patients receive a placebo and multivitamin orally each day for 52 weeks.
- Supplementation arm (multivitamin, cholecalciferol) (Type: EXPERIMENTAL): Patients receive a multivitamin and cholecalciferol supplement orally each day for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).